Current approach to down-staging of hepatocellular carcinoma prior to liver transplantation

Current Opinion in Organ Transplantation

Volumn 13, Issue 3, 2008, Pages 234-240

  Hanje, A James ^a   Yao, Francis Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Down staging; Hepatocellular carcinoma; Orthotopic liver transplantation

Indexed keywords

CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; RADIOFREQUENCY ABLATION; REVIEW; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR VOLUME; UNITED STATES; LIVER; LIVER TUMOR; PATHOLOGY; PATIENT SELECTION;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM STAGING; PATIENT SELECTION;

EID: 54549096903     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3282fc2633     Document Type: Review

References (45)

1. Befeler AS, Di Bisceglie AM. Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology 2002; 122:1609-1619.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340:745-750.
3. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160:3227- 3330.
4. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43:1303-1310.
5. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334:693-699.
6. Llovet JM, Bruix J, Fuster J, et al. Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology 1998; 27:1572-1577.
7. Hayashi P, Trotter J, Forman L, et al. Impact of pretransplant diagnosis of hepatocellular carcinoma on cadaveric liver allocation in the era of MELD. Liver Transpl 2004; 10:42-48.
8. United Network for Organ Sharing. Policy 3.6. http://www.unos.org/ policiesandbylaws/ policies.asp?resources=true. [Accessed November 2007]
9. Wiesner RH, Freeman RB, Mulligan DC. Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy. Gastroenterology 2004; 127 (Suppl 1):S261-S267.
10. Kirmlioglu H, Dvorchick I, Ruppert K, et al. Hepatocellular carcinoma in native livers from patients treated with orthotopic liver transplantation: biologic and therapeutic implication. Hepatology 2001; 34:502-510.
11. Klintmalm GB. Liver transplantation for hepatocellular carcinoma: a registry report of the impact of tumor characteristics on outcome. Ann Surg 1998; 228:479-490.
12. Tamura S, Kato T, Berho M, et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001; 136:25- 30.
13. Cillo U, Vitale A, Bassanello M, et al. Liver transplantation for the treatment of moderately or well differentiated hepatocellular carcinoma. Ann Surg 2004; 239:150-159.
14. Jonas S, Bechstein WO, Steinmuller T, et al. Vascular invasion and histologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33:1080-1086.
15. Hemming AW, Cattral MS, Reed AI, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001; 233:652-659.
16. Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biologic selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl 2006; 12:1260-1267. This study included a majority of patients with HCC initially exceeding Milan criteria who underwent liver transplantation if they showed objective response to TACE (effectively down-staged) based on the RECIST criteria. Despite a high dropout rate in the group exceeding Milan criteria, 5-year recurrence-free survival for those exceeding Milan criteria but responded to TACE was similar to those within Milan criteria.
17. Herrero JI, Sangro B, Quiroga J, et al. Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. Liver Transpl 2001; 7:631-636.
18. Iwatsuki S, Dvorchik I, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma: a proposal of a prognostic scoring system. J Am Coll Surg 2000; 191:389-394.
19. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33:1394-1403.
20. Yao FY, Xiao L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007; 7:2587-2596.
21. Duffy JP, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg 2007; 246:502-511.
22. Roayaie S, Llovet J. Liver transplantation for hepatocellular carcinoma: is expansion of criteria justified? Clin Liver Dis 2005; 9:315-328.
23. Mazzaferro V. Results of liver transplantation: with or without Milan criteria? Liver Transpl 2007; 13:S44-S47.
24. Freeman RB, Edwards EB, Harper AM. Waiting list removal rates among patients with chronic and malignant liver diseases. Am J Transplant 2006; 6:1416-1421.
25. Graziadei IW, Sandmueller H, Waldenberger P, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9:557-563.
26. Lu DS, Yu NC, Raman SS, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41:1130-1137.
27. Maddala YK, Stadheim L, Andrews JC, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004; 10:449-455.
28. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, et al. Impact of pretransplantation transarterial chemoembolization on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005; 11: 767-775.
29. Harnois DM, Steers J, Andrews JC, et al. Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. Liver Transpl Surg 1999; 5:192-199.
30. Fisher RA, Maluf D, Cotterell AH, et al. Nonresective ablation therapy for hepatocellular carcinoma: effectiveness measured by intention-to-treat and dropout from liver transplant waiting list. Clin Transplant 2004; 18:502- 512.
31. Bharat A, Brown DB, Crippin JS, et al. Preliver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg 2006; 203:411-420.
32. Oldhafer KJ, Chavan A, Fruhauf NR, et al. Arterial chemoembolization before liver transplantation in patients with hepatocellular carcinoma: marked tumor necrosis, but no survival benefit? J Hepatol 1998; 29:953-959.
33. Millonig G, Graziadei I, Freund MC, et al. Response to chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl 2007; 13:272-279. This paper included a subgroup analysis of patients exceeding Milan criteria who responded to TACE (effectively down-staged). These patients were found to have acceptable 1, 2, and 5-year intention-to-treat survival.
34. Yao FY, Kinkhabwala M, LaBerge J, et al. The impact of preoperative locoregional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transpl 2005; 5:795-804.
35. Majno PE, Adam R, Bismuth H, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 2004; 239:150-159.
36. Roayaie S, Frischer JS, Emre SH, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002; 235:533-539.
37. Yao FY, Hirose R, Laberge J, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005; 11:1505-1514.
38. Marsh JW, Dvorchik I, Iwatsuki S. UNOS policy in upgrading patients with HCC awaiting liver transplantation: too little too late [abstract]. Transplantation 2000; 69 (Suppl):S139.
39. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35:519-524.
40. Yao FY, Kerlan R, Davern TJ, et al. Excellent long-term outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis [abstract]. Hepatology 2007; 46 (Suppl):309A.
41. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
42. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol 2005; 16:1627- 1639.
43. Kulik LM, Atassi B, Van Holsbeeck L, et al. Yttrium-90 microspheres (Thera- Sphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94:572- 586.
44. Llovet J, Ricci S, Mazzafero V, et al. Sorafenib improves survival in advanced hepatocellular carcinoma (HCC): results of a phase III randomized, placebocontrolled trial (SHARP trial) [meeting abstract]. J Clin Oncol 2007; 25:18S.
45. Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2007; 26 November [Epub ahead of print].